Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia

Arsenic trioxide has become the treatment of choice for patients with acute promyelocytic leukaemia. Cardiovascular toxicity is known to occur with this therapy, in particular heart rhythm disorders due to QT interval prolongation. We present a case of ventricular arrhythmia with no QT prolongation...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of the Royal College of Physicians of Edinburgh Vol. 41; no. 2; pp. 117 - 118
Main Authors:	Ducas, R A, Seftel, M D, Ducas, J, Seifer, C
Format:	Journal Article
Language:	English
Published:	Scotland 01-06-2011
Subjects:	Adult Anti-Arrhythmia Agents - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Arsenicals - adverse effects Arsenicals - therapeutic use Electrocardiography Female Humans Leukemia, Promyelocytic, Acute - drug therapy Magnesium - therapeutic use Manitoba Metoprolol - therapeutic use Oxides - adverse effects Oxides - therapeutic use Potassium - therapeutic use Tachycardia, Ventricular - chemically induced Tachycardia, Ventricular - diagnosis Tachycardia, Ventricular - drug therapy Manitoba
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Arsenic trioxide has become the treatment of choice for patients with acute promyelocytic leukaemia. Cardiovascular toxicity is known to occur with this therapy, in particular heart rhythm disorders due to QT interval prolongation. We present a case of ventricular arrhythmia with no QT prolongation in a patient receiving arsenic trioxide therapy.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	1478-2715 2042-8189
DOI:	10.4997/JRCPE.2011.204